IQVIA (IQV) Reports Q3 Earnings: What Key Metrics Have to Say

IQVIA Holdings (IQV) reported Q3 2025 revenue of $4.1 billion, a 5.2% year-over-year increase, and EPS of $3.00, both surpassing analyst consensus estimates by 0.86% and 1.35% respectively. While headline figures beat, segment performance was mixed; Contract Sales & Medical Solutions revenue grew 16.1% year-over-year and significantly exceeded estimates, as did its segment profit, but Technology & Analytics Solutions revenue and profit slightly missed expectations. Despite the positive earnings surprise and a recent 20.3% stock gain, IQVIA holds a Zacks Rank #4 (Sell), indicating potential near-term underperformance.

Analysis

IQVIA Holdings (IQV) reported robust Q3 2025 headline results, with revenue reaching $4.1 billion, a 5.2% year-over-year increase, and EPS of $3.00. These figures surpassed consensus estimates by 0.86% and 1.35% respectively, indicating strong top- and bottom-line performance for the quarter. This overall beat suggests effective operational execution against analyst expectations.

A deeper dive into segment performance reveals a mixed picture. The Contract Sales & Medical Solutions segment was a significant outperformer, reporting revenues of $209 million against an estimated $180.27 million, marking a substantial 16.1% year-over-year growth, coupled with a strong segment profit beat. Conversely, the Technology & Analytics Solutions segment underperformed, missing revenue estimates with $1.63 billion against a $1.66 billion estimate, and falling short on segment profit at $370 million versus the $412.55 million average estimate.

Despite the positive earnings surprise and a strong +20.3% stock return over the past month, significantly outpacing the S&P 500's +3.6% change, IQVIA currently holds a Zacks Rank #4 (Sell). This rating suggests a potential for near-term underperformance relative to the broader market, creating a notable divergence between recent market momentum and analyst outlook.

Key Decisions for Investors

• Investors should scrutinize the mixed segmental performance, particularly the underperformance in Technology & Analytics Solutions, to assess its long-term impact on IQV's growth trajectory.
• Given the Zacks Rank #4 (Sell) despite recent strong stock performance and earnings beats, investors should evaluate if the current valuation reflects potential future headwinds or if the market is overreacting to short-term positive news.
• Consider monitoring future backlog trends and segment profit margins, especially in the underperforming segments, as these will be critical indicators for sustained operational health.